About this paper
Sponsors and clinical research organizations (CROs) are being very cautious in their utilization of adaptive clinical trial designs. And well they should be. While under the right circumstances, clinical trials can enhance the ethical treatment of patients, enable better decisions faster and help minimize the cost of clinical development, it is important to keep in mind that adaptive trials will not always be appropriate. This paper from Elsevier Business Intelligence discusses how adaptive clinical trials can provide a better way to explore and demonstrate the efficacy and safety of investigational products, while also emphasizing the point that a trial that forgoes validity for novelty is not a good trial.
SAS helps 80,000 organisations around the world take their data… And do amazing things… We help organisations turn large amounts of data into knowledge they can use, and we do it better than anyone. It’s no wonder an overwhelming majority of customers continue to use SAS year after year. Find out more, Why SAS?